Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Faron Pharmaceuticals OY (FARN) NPV

Sell:390.00p Buy:400.00p 0 Change: 2.50p (0.63%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:390.00p
Buy:400.00p
Change: 2.50p (0.63%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:390.00p
Buy:400.00p
Change: 2.50p (0.63%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.

Contact details

Address:
Joukahaisenkatu 6
TURKU
20520
Finland
Telephone:
+358 (02) 4695151
Website:
https://www.faron.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 26 August 2021 26/08/21
AGM 23 April 2021 23/04/21
Annual report 25 March 2021 25/03/21
Final results 25 March 2021 25/03/21

General stock information

EPIC:
FARN
ISIN:
FI4000153309
Market cap:
£199.31 million
Shares in issue:
50.46 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Markku Jalkanen
    Chief Executive Officer, Founder, Member of the Executive Board
  • Yrjo Wichmann
    Chief Financial Officer, Member of the Executive Board
  • Mikael Maksimow
    Vice President Operations
  • Ilse Piippo
    Vice President Drug Development, Chief Medical Officer
  • Matti Karvonen
    Medical Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.